Zhejiang U | College of Pharmaceutical Sciences | 中文版
     
     
Feng ZHU - IDRC - Chongqing University
ABOUT THE PRINCIPAL INVESTIGATOR

Dr. Feng ZHU

Professor, Doctoral advisor, H-index & My Citations (Google Scholar)

Vice President of Youth Committee of CNPHARS Analytical Pharmacology and Chongqing Bioinformatics Society; Member of Analytical Pharmacology Committee of CNPHARS, Computational Chemistry Committee of CCS and Task Force on Bioinformatics Committee of CCF

zhufeng@zju.edu.cn (primary), prof.zhufeng@gmail.com; +86-571-88208444
PERSONAL DETAILS
Research Interests: Medicinal Chemistry, Drug Design, Target Discovery, Bioinformatics and System Biology

Based on the artificial intelligence and OMIC (proteomics and metabolomics) technologies, we conduct systematical exploration on the druggability and system profile of therapeutic drug targets, develop novel methods and online tools for target discovery, and further study the mechanism underlying the interaction between drugs and their corresponding targets.
  Academic Appointments
  Educational Qualifications
  Honors and Awards
  • Leading Talent of the Chinese MOST Science and Technology Innovation Program (2020)

  • Key Member of the Innovative Team of the Chinese MOST Science & Technology Nova Program (2019)

  • Honorable Professor of the International Recruitment Program (Youth) of China (2014)

  • Honorable Professor of the International Recruitment Program of Zhejiang Province (2018)

  • Honorable Professor of the High-level Personnel of Zhejiang Province (2019)

  • Chonqing Science and Technology Award First Prize of Scientific and Technological Progress (2019)

  • High-level Personnel of Chongqing Municipality, the Second Category (2014)

  • Tang Lixin Award of Outstanding Research Performance (2015)

  • 2019 Annual Award of Outstanding Professor of Zhejiang University, College/School Level (2020)

  • 2018 Annual Award of Outstanding Professor of Zhejiang University, College/School Level (2019)

  • Honorable Professor of the Recruitment Program of Zhejiang University (2017)

  • Honorable Professor of the Recruitment Program of Chongqing University (2013)
  Research Grants (PI: Principal Investigator; PP: Project Participant)
    Project on Going

  • 2020.01 - (PI): National Natural Science Foundation of China - The Collaboration Program (U1909208)

  • 2020.01 - (PI): Key Research and Development Program of Zhejiang Province (2020C03010)

  • 2019.01 - (PI): National Natural Science Foundation of China - The General Program (81872798)

  • 2018.09 - (PP): National Key Research and Development Program of China (2018YFC0910500)

  • 2018.01 - (PI): Zhejiang University Youth Research Innovation Grant (2018QNA7023)

  • 2017.07 - (PI): Zhejiang University "100-Plan Professor" Grant (ZJU2017070)

    • Project Finished

  • 2016.08 - (PI): National Key Research and Development Program of China (2016YFC0902200)

  • 2015.12 - (PI): Chongqing Special Funds for (Chemical) Drug Discovery (cstc2015zdcy-ztzx120003)

  • 2014.06 - (PI): International Recruitment Program (Youth) of China (IRPC-Y-CQU2014-ZF)

  • 2014.06 - (PI): Fundamental Research Funds for the Central Universities (CDJZR14 46 88 01, evaluated as "Excellent")

  • 2013.01 - (PI): Fundamental Research Funds for the Central Universities (CQDXWL-2012-Z003, evaluated as "Excellent")

  • 2013.01 - (PI): National Natural Science Foundation of China - The Youth Program (81202459)

  • 2012.09 - (PI): Chongqing Natural Science Foundation (cstc2012jjA10116)

  • 2012.07 - (PI): Youth 100 Talents Program of Chongqing University (0903005203176, evaluated as "Excellent")
  Selected Publications (*corresponding author; highlighted graphic abstract; download PDF; &co-first author)
  1. Q. X. Yang, Y. X. Wang, Y. Zhang, F. C. Li, W. Q. Xia, Y. Zhou, Y. Q. Qiu, H. L. Li, F. Zhu*. NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data. Nucleic Acids Res (impact factor of the publication year: 11.147, 生物一区 TOP 期刊). doi: 10.1093/nar/gkaa258 (2020).  

  2. J. Y. Yin, W. Sun, F. C. Li, J. J. Hong, X. X. Li, Y. Zhou, Y. J. Lu, M. Z. Liu, X. Zhang, N. Chen, X. P. Jin, J. Xue, S. Zeng*, L. S. Yu*, F. Zhu*. VARIDT 1.0: variability of drug transporter database. Nucleic Acids Res (impact factor of the publication year: 11.147, 生物一区 TOP 期刊). 48(D1): 1042-1050 (2020).  

  3. Y. X. Wang, S. Zhang, F. C. Li, Y. Zhou, Y. Zhang, Z. W. Wang, R. Y. Zhang, J. Zhu, Y. X. Ren, Y. Tan, C. Qin, Y. H. Li, X. X. Li, Y. Z. Chen*, F. Zhu*. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res (impact factor of the publication year: 11.147, 生物一区 TOP 期刊). 48(D1): 1031-1041 (2020).  

  4. Y. H. Li, X. X. Li, J. J. Hong, Y. X. Wang, J. B. Fu, H. Yang, C. Y. Yu, F. C. Li, J. Hu, W. W. Xue, Y. Y. Jiang, Y. Z. Chen*, F. Zhu*. Clinical trials, progression-speed differentiating features, and swiftness rule of the innovative targets of first-in-class drugs. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(2): 649-662 (2020).  

  5. J. Tang, J. B. Fu, Y. X. Wang, B. Li, Y. H. Li, Q. X. Yang, X. J. Cui, J. J. Hong, X. F. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. ANPELA: analysis and performance-assessment of the label-free quantification workflow for metaproteomic studies. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(2): 621-636 (2020).  

  6. Q. X. Yang, B. Li, J. Tang, X. J. Cui, Y. X. Wang, X. F. Li, J. Hu, Y. Z. Chen, W. W. Xue, Y. Lou, Y. Q. Qiu*, F. Zhu*. Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(3): 1058-1068 (2020).  

  7. Z. J. Han, W. W. Xue, L. Tao, Y. Lou, Y. Q. Qiu*, F. Zhu*. Genome-wide identification and analysis of the eQTL lncRNAs in multiple sclerosis based on RNA-seq data. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(3): 1023-1037 (2020).  

  8. F. C. Li, Y. Zhou, X. Y. Zhang, J. Tang, Q. X. Yang, Y. Zhang, Y. C. Luo, J. Hu*, W. W. Xue, Y. Q. Qiu, Q. J. He, B. Yang, F. Zhu*. SSizer: determining the sample sufficiency for comparative biological study. J Mol Bio (impact factor of the publication year: 5.067, 生物二区 TOP 期刊). 432(11): 3411-3421 (2020).  

  9. J. J. Hong, Y. C. Luo, Y. Zhang, J. B. Ying, W. W. Xue, T. Xie, L. Tao*, F. Zhu*. Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). doi: 10.1093/bib/bbz081 (2019).  

  10. J. J. Hong, Y. C. Luo, M. J. Mou, J. B. Fu, Y. Zhang, W. W. Xue, T. Xie, L. Tao*, Y. Lou*, F. Zhu*. Convolutional neural network-based annotation of bacterial type IV secretion system effectors with enhanced accuracy and reduced false discovery. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). doi: 10.1093/bib/bbz120 (2019).  

  11. Q. X. Yang, J. J. Hong, Y. Li, W. W. Xue, S. Li*, H. Yang*, F. Zhu*. A novel bioinformatics approach to identify the consistently well-performing normalization strategy for current metabolomic studies. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). doi: 10.1093/bib/bbz137 (2019).  

  12. J. Tang, J. B. Fu, Y. X. Wang, Y. C. Luo, Q. X. Yang, B. Li, G. Tu, J. J. Hong, X. J. Cui, Y. Z. Chen, L. X. Yao, W. W. Xue, F. Zhu*. Simultaneous improvement in the precision, accuracy and robustness of label-free proteome quantification by optimizing data manipulation chains. Mol Cell Proteomics (impact factor of the publication year: 5.236, 生物二区 TOP 期刊). 18(8): 1683-1699 (2019).  
    13. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.27% in 2020.

  13. Y. Zhang, J. B. Ying, J. J. Hong, F. C. Li, T. T. Fu, F. Y. Yang, G. X. Zheng, X. J. Yao, Y. Lou, Y. Q. Qiu, W. W. Xue*, F. Zhu*. How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from Trichostatin A enantiomers based on molecular dynamics. ACS Chem Neurosci (impact factor of the publication year: 4.211, 化学二区 TOP 期刊). 10(5): 2467-2480 (2019).  
    14. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.90% in 2020.
    Cover Article:

  14. Q. X. Yang, Y. X. Wang, F. C. Li, S. Zhang, Y. C. Luo, Y. Li, J. Tang, B. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility. CNS Neurosci Ther (impact factor of the publication year: 3.394, 医学二区期刊). 25(9): 1054-1063 (2019).  
    15. Cover Article:

  15. Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, Y. Zhang, S. Li, F. Y. Yang, Q. Sun, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res (impact factor of the publication year: 11.561, 生物一区 TOP 期刊). 46(D1): 1121-1127 (2018).  
    16.
    ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.16% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.36% in 2018.
    Highlights by Experts in Subject Area:
    • Introduced by OMICTOOLS as "useful for facilitating patient focused research, discovery and clinical investigations of the targeted therapeutics".

  16. F. Zhu*, X. X. Li, S. Y. Yang, Y. Z. Chen*. Clinical success of drug targets prospectively predicted by in-silico study. Trends Pharmacol Sci (impact factor of the publication year: 12.797, 医学一区 TOP 期刊). 39(3): 229-231 (2018).  
    17. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.34% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.10% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.21% in 2018.

  17. W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci (impact factor of the publication year: 4.211, 化学二区 TOP 期刊). 9(5): 1128-1140 (2018).  
    18. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.29% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.29% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 1.11% in 2018.

  18. F. Y. Yang, G. X. Zheng, T. T. Fu, X. F. Li, G. Tu, Y. H. Li, X. J. Yao, W. W. Xue*, F. Zhu*. Prediction of binding mode and resistance profile for dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase associated ribonuclease H. Phys Chem Chem Phys (impact factor of the publication year: 4.123, 化学二区 TOP 期刊). 20(37): 23873-23884 (2018).  
    19. Back Cover Article:

  19. Z. J. Han, W. W. Xue, L. Tao, F. Zhu*. Identification of novel immune-relevant drug target genes for alzheimer's disease by combining ontology inference with network analysis. CNS Neurosci Ther (impact factor of the publication year: 3.495, 医学二区期刊). 24(12): 1253-1263 (2018).  
    20. Cover Article:

  20. B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res (impact factor of the publication year: 10.162, 生物一区 TOP 期刊). 45(W1): 162-170 (2017).  
    21. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.09% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.27% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 2.98% in 2018.
    Highlights by Experts in Subject Area:
    • Introduced by OMICTOOLS as "provided valuable guidance to the selection of suitable algorithm in metabolomics".
    • Discussed in StackExchange as "works fine" and "corrections for batches without QC options".

  21. P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem Neurosci (impact factor of the publication year: 4.348, 化学二区 TOP 期刊). 8(6): 1416-1428 (2017).  
    22. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.80% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.32% in 2019.

  22. H. Yang, C. Qin, Y. H. Li, L. Tao, J. Zhou, C. Y. Yu, F. Xu, Z. Chen, F. Zhu*, Y. Z. Chen*. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res (impact factor of the publication year: 9.202, 生物一区 TOP 期刊). 44(D1): 1069-1074 (2016).  
    23. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.79% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.66% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.71% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.87% in 2017.

  23. F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, F. Xu, L. Zhang, Y. Song, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (impact factor of the publication year: 8.026, 生物一区 TOP 期刊). 40(D1): 1128-1136 (2012).  
    24. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.66% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.60% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.62% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.31% in 2017.

    Highlights by Experts in Subject Area:

    • "FACULTYof1000" as "the top 2% of published articles in biology and medicine" and "a most useful resource for scientists and companies working on drug discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations".
    • Prof. Chris Southan in his blog as "Therapeutic Target Database in PubChem".

  24. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A (impact factor of the publication year: 9.432, 综合性一区 TOP 期刊). 108(31): 12943-12948 (2011).  
    25. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.90% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.94% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.91% in 2017.
    Highlights by Experts in Subject Area: Media Coverage & News Report:

  25. F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Res (impact factor of the publication year: 7.479, 生物一区 TOP 期刊). 38(D1): 787-791 (2010).  
    26. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 2.95% in 2017.

  26. F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profile of successful targets. J Pharmacol Exp Ther (impact factor of the publication year: 3.867, 医学二区 TOP 期刊). 330(1): 304-315 (2009).  
    27. Successful Validation of the Constructed Model:
    • Pasireotide targeting Somatostatin receptor 1 was approved by FDA in 2011.
    • Fingolimod targeting S1P receptor was approved by FDA in 2010.
    • Ecallantide targeting Plasma Kallikrein was approved by FDA in 2009.
    • Cinryze targeting C1 esterase was approved by FDA in 2009.
    • Icatibant targeting BK-2 receptor was approved by FDA in 2008.
    • Plerixafor targeting CXCR4 was approved by FDA in 2008.
  Licensed Patents and Copyrights
  1. F. Zhu, Q. X. Yang, B. Li, Y. X. Wang. A software tool for evaluating mass-spectrometry-based metabolomic data from multiple perspectives. Software Copyright 2020SR0275177 approved by National Copyright Administration of China (2020)

  2. F. Zhu, S. Zeng, J. Y. Yin, F. C. Li. A software tool for analyzing the interplay among the variabilities of drug transporters. Software Copyright 2020SR0275172 approved by National Copyright Administration of China (2020)

  3. F. Zhu, J. Tang, J. B. Fu, Y. X. Wang. A software tool for assessing label-free proteome quantification from multiple perspectives. Software Copyright 2020SR0274135 approved by National Copyright Administration of China (2020)

  4. F. Zhu, J. J. Hong, J. Hu, L. Tao. A software tool for discovering the bacterial type-IV secreting system effector protein. Software Copyright 2020SR0274064 approved by National Copyright Administration of China (2020)
  Hosted Conference and Symposium
  Invited Speaker of International/Domestic Conference
  Reviewer of Esteemed Journals (ordered alphabetically)
ACS Chem Neurosci; Aging Dis; Amino Acids; Anal Chem; Artif Cells Nanomed Biotechnol; Bioinformatics; BMC Bioinformatics; Brief Bioinform; CNS Neurosci Ther; Curr Pharm Des; Drug Dev Res; Expert Opin Ther Targets; Front Pharmacol; J Chem Inf Model; J Mol Graph Model; J Pharmacol Exp Ther; Med Res Rev; Microb Pathog; Mol Biosyst; Mol Pharmaceut; Mol Pharmacol; Mol Simul; Pharmacol Res; Phys Chem Chem Phys; Nucleic Acids Res; Sci Rep
  Editorial Board Member/Associate Editor of Journals (ordered alphabetically)
Comput Biol Med; Curr Bioinform; J Alzheimers Dis; Prog Pharm Sci; Protein Pept Lett
IDRB: Innovative Drug Research and Bioinformatics Group


All rights are reserved by: Innovative Drug Research and Bioinformatics Group (IDRB)
College of Pharmaceutical Sciences, Zhejiang University
Hangzhou, P.R. China, 310058.
Contact number: (86 - 571)88208444
ICP ID: 浙ICP备18036997号-1

Last Update: